Physician profile
Kyle A Przekaza
NPI 1659702264
$673.50
in general payments reported to CMS, 2019-2025
10 companies · $77.19 in 2025
The $77.19 reported for 2025 was less than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $206 · 2022: $180 · 2023: $62.70 · 2024: $148 · 2025: $77.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $287.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $224.70 | 2021-2025 | Zilretta, Iovera, Exparel |
| Ferring Pharmaceuticals INC. | $119.98 | 2021-2024 | Euflexxa |
| Innovation Technologies INC | $101.70 | 2024 | Irrisept |
| Bioventus LLC | $78.54 | 2021-2023 | Durolane |
| Pacira Therapeutics, INC. | $39.04 | 2021 | |
| Orthofix Medical, INC. | $33.83 | 2025 | Spinal-Stim |
| Smith+Nephew, INC. | $20.29 | 2021 | |
| Endo Pharmaceuticals INC. | $19.58 | 2021 | |
| Convatec INC. | $19.54 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $16.30 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Przekaza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.